224 related articles for article (PubMed ID: 11765378)
1. Retinoid therapy of childhood cancer.
Reynolds CP; Lemons RS
Hematol Oncol Clin North Am; 2001 Oct; 15(5):867-910. PubMed ID: 11765378
[TBL] [Abstract][Full Text] [Related]
2. Retinoid therapy of high-risk neuroblastoma.
Reynolds CP; Matthay KK; Villablanca JG; Maurer BJ
Cancer Lett; 2003 Jul; 197(1-2):185-92. PubMed ID: 12880980
[TBL] [Abstract][Full Text] [Related]
3. Differentiating agents in pediatric malignancies: retinoids in neuroblastoma.
Reynolds CP
Curr Oncol Rep; 2000 Nov; 2(6):511-8. PubMed ID: 11122886
[TBL] [Abstract][Full Text] [Related]
4. Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide.
Reynolds CP; Wang Y; Melton LJ; Einhorn PA; Slamon DJ; Maurer BJ
Med Pediatr Oncol; 2000 Dec; 35(6):597-602. PubMed ID: 11107126
[TBL] [Abstract][Full Text] [Related]
5. Retinoids in pediatric onco-hematology: the model of acute promyelocytic leukemia and neuroblastoma.
Masetti R; Biagi C; Zama D; Vendemini F; Martoni A; Morello W; Gasperini P; Pession A
Adv Ther; 2012 Sep; 29(9):747-62. PubMed ID: 22941525
[TBL] [Abstract][Full Text] [Related]
6. Clinical and pharmacokinetic studies of all-trans-retinoic acid in pediatric patients with cancer.
Adamson PC
Leukemia; 1994; 8 Suppl 3():S22-5. PubMed ID: 7808020
[TBL] [Abstract][Full Text] [Related]
7. Influence of isomerisation on the growth inhibitory effects and cellular activity of 13-cis and all-trans retinoic acid in neuroblastoma cells.
Veal GJ; Errington J; Redfern CP; Pearson AD; Boddy AV
Biochem Pharmacol; 2002 Jan; 63(2):207-15. PubMed ID: 11841795
[TBL] [Abstract][Full Text] [Related]
8. 9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia.
Miller WH; Jakubowski A; Tong WP; Miller VA; Rigas JR; Benedetti F; Gill GM; Truglia JA; Ulm E; Shirley M
Blood; 1995 Jun; 85(11):3021-7. PubMed ID: 7756637
[TBL] [Abstract][Full Text] [Related]
9. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
Kitamura K; Kiyoi H; Yoshida H; Tobita T; Takeshita A; Ohno R; Naoe T
Cancer Chemother Pharmacol; 1997; 40 Suppl():S36-41. PubMed ID: 9272132
[TBL] [Abstract][Full Text] [Related]
10. Superior effect of 9-cis retinoic acid (RA) compared with all-trans RA and 13-cis RA on the inhibition of clonogenic cell growth and the induction of apoptosis in OCI/AML-2 subclones: is the p53 pathway involved?
Koistinen P; Zheng A; Säily M; Siitonen T; Mäntymaa P; Savolainen ER
Br J Haematol; 2002 Aug; 118(2):401-10. PubMed ID: 12139723
[TBL] [Abstract][Full Text] [Related]
11. The vitamin A analogues: 13-cis retinoic acid, 9-cis retinoic acid, and Ro 13-6307 inhibit neuroblastoma tumour growth in vivo.
Ponthan F; Borgström P; Hassan M; Wassberg E; Redfern CP; Kogner P
Med Pediatr Oncol; 2001 Jan; 36(1):127-31. PubMed ID: 11464864
[TBL] [Abstract][Full Text] [Related]
12. All trans retinoic acid and cancer.
Siddikuzzaman ; Guruvayoorappan C; Berlin Grace VM
Immunopharmacol Immunotoxicol; 2011 Jun; 33(2):241-9. PubMed ID: 20929432
[TBL] [Abstract][Full Text] [Related]
13. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid.
Tobita T; Takeshita A; Kitamura K; Ohnishi K; Yanagi M; Hiraoka A; Karasuno T; Takeuchi M; Miyawaki S; Ueda R; Naoe T; Ohno R
Blood; 1997 Aug; 90(3):967-73. PubMed ID: 9242525
[TBL] [Abstract][Full Text] [Related]
14. Effects of novel RAR- and RXR-selective retinoids on myeloid leukemic proliferation and differentiation in vitro.
Shiohara M; Dawson MI; Hobbs PD; Sawai N; Higuchi T; Koike K; Komiyama A; Koeffler HP
Blood; 1999 Mar; 93(6):2057-66. PubMed ID: 10068679
[TBL] [Abstract][Full Text] [Related]
15. Clinical and pharmacokinetic studies of all-trans-retinoic acid in pediatric patients with cancer.
Adamson PC
Leukemia; 1994 Nov; 8(11):1813-6. PubMed ID: 7967727
[TBL] [Abstract][Full Text] [Related]
16. Differentiating therapy with all-trans retinoic acid in acute myeloid leukemia.
Tallman MS
Leukemia; 1996 Apr; 10 Suppl 1():S12-5. PubMed ID: 8618462
[TBL] [Abstract][Full Text] [Related]
17. Synergistic induction of apoptosis of neuroblastoma by fenretinide or CD437 in combination with chemotherapeutic drugs.
Lovat PE; Ranalli M; Bernassola F; Tilby M; Malcolm AJ; Pearson AD; Piacentini M; Melino G; Redfern CP
Int J Cancer; 2000 Dec; 88(6):977-85. PubMed ID: 11093824
[TBL] [Abstract][Full Text] [Related]
18. Trans-retinoic acid and related differentiation agents.
Parkinson DR; Smith MA; Cheson BD; Stevenson HC; Friedman MA
Semin Oncol; 1992 Dec; 19(6):734-41. PubMed ID: 1462170
[TBL] [Abstract][Full Text] [Related]
19. Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance.
Duffy DJ; Krstic A; Halasz M; Schwarzl T; Konietzny A; Iljin K; Higgins DG; Kolch W
Genome Med; 2017 Feb; 9(1):15. PubMed ID: 28187790
[TBL] [Abstract][Full Text] [Related]
20. Differentiating therapy in acute myeloid leukemia.
Tallman MS
Leukemia; 1996 Aug; 10(8):1262-8. PubMed ID: 8709629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
